Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 184
- Registration Number
- NCT06088654
- Locations
- ๐บ๐ธ
City of Hope, Duarte, California, United States
๐บ๐ธCedars Sinai, Los Angeles, California, United States
๐บ๐ธSiteman Cancer Center, Saint Louis, Missouri, United States
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
- Conditions
- Interventions
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 70
- Registration Number
- NCT05742607
- Locations
- ๐ฌ๐ท
University General Hospital of Patras, Patras, Greece
๐ซ๐ทCharles Nicolle Hospital, Rouen, France
๐ญ๐บPulmonology Institute Torokbalint, Torokbalint, Hungary
Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-03-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT05321147
- Locations
- ๐ฐ๐ท
Inje University Busan Paik Hospital, Busan, Korea, Republic of
๐บ๐ธUniversity of Alabama at Birmingham- O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States
๐บ๐ธIndiana University School of Medicine, Indianapolis, Indiana, United States
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 170
- Registration Number
- NCT03902184
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธUniversity of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California, United States
๐บ๐ธInova Health Care Services, Fairfax, Virginia, United States
IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 73
- Registration Number
- NCT03665129
- Locations
- ๐บ๐ธ
ICAHN School of Medicine at Mount Sinai, New York, New York, United States
๐ซ๐ทCentre Hospitalier Universitaire- Hรดpital Nord Laennec, Nantes, France
๐บ๐ธPark Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota, United States
Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2015-12-31
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 143
- Registration Number
- NCT02643550
- Locations
- ๐บ๐ธ
University of Maryland, Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States
๐บ๐ธFox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)
- First Posted Date
- 2015-10-30
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 44
- Registration Number
- NCT02593045
- Locations
- ๐บ๐ธ
Ohio State University, Columbus, Ohio, United States
๐บ๐ธStanford Cancer Center, Stanford, California, United States
๐ณ๐ฑLeiden University Medical Center, Leiden, Netherlands
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
- First Posted Date
- 2015-09-23
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 22
- Registration Number
- NCT02557516
- Locations
- ๐บ๐ธ
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
- Conditions
- Interventions
- First Posted Date
- 2015-01-06
- Last Posted Date
- 2017-01-04
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 3
- Registration Number
- NCT02331875
- Locations
- ๐ช๐ธ
Instituto Catalan de Oncologia - L'Hospitalet, L'Hospitalet de Llobregat Barcelona, Spain
๐ช๐ธHospital Universitario La Paz, Madrid, Spain
๐ฉ๐ชCharitรฉ University Medicine Berlin, Berlin, Germany
Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)
- Conditions
- Interventions
- First Posted Date
- 2012-09-18
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 152
- Registration Number
- NCT01687387
- Locations
- ๐ซ๐ท
Hรดpital Claude Huriez, Lille, France
๐ซ๐ทCHU Angers, Angers, France
๐ซ๐ทCHU d'Amiens, Amiens, France